This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I42.20 (non-obstructive hypertrophic cardiomyopathy) | Special Copayment Reduction: V127 (rare disease) |
| B. Synonyms | Not applicable |
| C. Adult onset | Likelihood of first presentation in adulthood: high — non-obstructive hypertrophic cardiomyopathy is sometimes diagnosed in childhood, but in more than half of patients it is first diagnosed in adulthood (20s~50s) prompted by exertional dyspnea, chest pain, syncope and the like, and even in carriers of gene mutations phenotypic expression often begins in adulthood. |
| 1. History | 1958 first autopsy report by Teare → 1960s hemodynamic studies by Braunwald → 1990s identification of gene mutations → 2022 FDA approval of mavacamten. |
| 2. Causes | Mutations in cardiac sarcomere protein genes. 9 or more genes, including MYH7 and MYBPC3. Autosomal dominant inheritance is the main mode. |
| 3. Genetics | MYH7 (β-myosin heavy chain) and MYBPC3 (cardiac myosin-binding protein C) mutations account for about 70% of the total. Incomplete penetrance leads to phenotypic diversity within families. |
| 4. General epidemiology | Frequency of about 1/500 in the general population. The non-obstructive subtype accounts for about 70% of hypertrophic cardiomyopathy. The most common cause of sudden death in athletes. |
| 5. Pathophysiology | Sarcomere protein mutation → myocardial hypertrophy, myocyte disarray, interstitial fibrosis → diastolic dysfunction, elevated left ventricular filling pressure → worsening myocardial ischemia. |
| 6. Symptoms | Exertional dyspnea (most common), chest pain, syncope or presyncope, palpitations. Sudden death without prior symptoms may be the first presentation. |
| 7. Signs | In the non-obstructive form, systolic murmur absent or mild. ECG abnormalities (left ventricular hypertrophy, ST·T-wave changes, abnormal Q waves). Asymmetric left ventricular hypertrophy on echocardiography. |
| 8. Screening | Regular echocardiography/ECG screening of first-degree relatives with a family history. Family genetic testing when a gene mutation is identified. Pre-participation cardiac screening of athletes. |
| 9. Diagnosis | Echocardiography (left ventricular wall thickness ≥15 mm, other causes excluded). Cardiac MRI (assessment of fibrosis). Gene panel testing. Stress testing (assessment of latent obstruction). |
| 10. Treatment | Symptom control with beta-blockers and calcium channel blockers (verapamil). Mavacamten (cardiac myosin inhibitor). ICD (high risk of sudden death). Anticoagulation for atrial fibrillation. |
| 11. Prognosis | Annual mortality less than 1% (specialist centers). Sudden death, heart failure and stroke are the main risks. The non-obstructive subtype is relatively favorable, but the prognosis is poor when fibrosis progresses. |
| 12. Prevention | Genetic counseling, family screening, avoidance of high-risk exercise. Prevention of sudden death by ICD implantation. Regular follow-up with cardiac imaging. |
| 13. References | Maron BJ, et al. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002 … and 9 other papers |
The historical description of hypertrophic cardiomyopathy begins in 1958 with the British pathologist Donald Teare's autopsies of 9 young athletes who had died suddenly. Reporting the distinctive pathological findings of asymmetric hypertrophy of the ventricular septum and disorganized arrangement of myocardial fibers (myofibrillar disarray) in these patients, Teare first used the term 'asymmetrical hypertrophy of the heart.' Later, in the early 1960s, Eugene Braunwald and colleagues in the United States analyzed in depth a group of patients with left ventricular outflow tract obstruction, characterized its hemodynamic features and established the name 'hypertrophic obstructive cardiomyopathy (HOCM).'
However, as later studies revealed that a considerable number of patients with hypertrophic cardiomyopathy have no left ventricular outflow tract obstruction, the need for subtype classification by the presence of obstruction was recognized. Non-obstructive hypertrophic cardiomyopathy (non-obstructive HCM) is defined as a left ventricular outflow tract pressure gradient of less than 30 mmHg both at rest and on provocation. In the 1970s~80s, advances in echocardiography made antemortem diagnosis possible, epidemiological studies began in earnest, and a prevalence of about 1/500 in the general population was confirmed.
The 1990s were the period when the molecular genetics revolution fundamentally changed the understanding of hypertrophic cardiomyopathy. In 1990, Jarcho et al. first linked mutations in the MYH7 gene (β-myosin heavy chain) to familial hypertrophic cardiomyopathy, and subsequently mutations in sarcomere protein genes such as MYBPC3 (cardiac myosin-binding protein C), TNNT2 (cardiac troponin T) and TNNI3 (cardiac troponin I) were discovered one after another. As hypertrophic cardiomyopathy was redefined as a 'sarcomere disease,' genetic testing became central to diagnosis and family counseling.
In the 2000s, as the clinical use of cardiac MRI (magnetic resonance imaging) expanded, the diagnostic and prognostic value of myocardial fibrosis (late gadolinium enhancement, LGE) was demonstrated. The association of the presence and extent of LGE with sudden death, heart failure and stroke was proven in large cohorts, and it is now essential for risk stratification. In May 2022, mavacamten (brand name Camzyos) was approved by the US FDA for symptomatic obstructive hypertrophic cardiomyopathy, opening the era of sarcomere-targeted therapies acting directly on the disease mechanism, and clinical trials in the non-obstructive subtype are also under way. In Korea, a multicenter registry (Korean HCM Registry) has been operating since the 2010s and is contributing to understanding of domestic epidemiology and clinical features.
Non-obstructive hypertrophic cardiomyopathy is an inherited heart disease caused mainly by pathogenic mutations in genes encoding the proteins that make up the cardiac sarcomere. The sarcomere is the contractile unit of the cardiomyocyte, and dysfunction of its constituent proteins leads to abnormally increased myocardial contractility, myocyte disarray, myocardial hypertrophy and interstitial fibrosis.
More than 27 genes associated with hypertrophic cardiomyopathy have been reported to date, but the clinically most important causative genes are as follows. MYH7 (β-myosin heavy chain gene, 14q11.2): accounts for about 25~35% of hypertrophic cardiomyopathy, and most mutations are missense variants. MYBPC3 (cardiac myosin-binding protein C gene, 11p11.2): the most common causative gene, accounting for about 25~40%; truncating variants are common, and it is often associated with relatively late expression and a mild phenotype. Others, including TNNT2 (cardiac troponin T), TNNI3 (cardiac troponin I), TPM1 (alpha-tropomyosin), MYL2·MYL3 (myosin light chains) and ACTC1 (cardiac alpha-actin), explain the remaining about 10~15%.
About 30~40% of patients with hypertrophic cardiomyopathy have no genetically identified mutation. These are called 'sarcomere-negative' hypertrophic cardiomyopathy, and as yet unidentified gene variants or a polygenic basis have been proposed. There are also 'phenocopies' that show a phenotype similar to hypertrophic cardiomyopathy and require differentiation. Fabry disease (GLA gene, X-linked), glycogen storage disease (Pompe disease, glycogen storage disease type II), Danon disease (LAMP2 gene) and transthyretin amyloidosis (ATTR) are representative; each has a specific treatment, so differential diagnosis is important.
Non-genetic causes include long-standing hypertension (hypertensive cardiac hypertrophy, LVH), athlete's heart and senile cardiac hypertrophy, but these differ from inherited hypertrophic cardiomyopathy in etiology and histological findings. In the non-obstructive subtype, there is no obstruction at rest, so even with provocative testing (Valsalva maneuver, exercise stress testing) the left ventricular outflow tract pressure gradient remains below 30 mmHg.
The mode of inheritance of hypertrophic cardiomyopathy is mostly autosomal dominant, with a 50% probability of the mutation being transmitted from an affected parent to a child. However, penetrance is incomplete, so some individuals carrying the same mutation may not express the phenotype, which must be emphasized in genetic counseling. Expressivity can also differ greatly even within a family, so clinical outcomes ranging from asymptomatic mild disease to heart failure and sudden death may occur in the same pedigree.
More than about 300 MYH7 mutations have been reported, and certain missense variants such as Arg403Gln, Arg453Cys and Arg719Trp in particular are associated with a severe phenotype (onset at a young age, severe hypertrophy, high risk of sudden death). MYBPC3 mutations mainly appear as insertions/deletions or splicing variants causing protein truncation, and phenotypic expression is relatively late (40s~60s), so a high proportion are diagnosed in or after adulthood. TNNT2 mutations are characterized by mild myocardial hypertrophy but a high risk of myocardial fibrosis and sudden death.
Carriers of compound heterozygous or double mutations tend to show more severe hypertrophy and symptoms at an earlier age than carriers of a single mutation. Currently, the standard for clinical genetic testing is panel-based next-generation sequencing (NGS) including from at least 5 (MYH7, MYBPC3, TNNT2, TNNI3, TPM1) up to dozens of hypertrophic cardiomyopathy-related genes. When a pathogenic variant has been identified in a family, targeted genetic testing directly checking first-degree relatives for that variant is recommended.
Genetic test results are classified as pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign or benign. A VUS is difficult to use directly in clinical decisions, and reclassification is carried out through functional analysis and family co-segregation studies. Even with a positive genetic test, no treatment is currently needed in a non-penetrant state, but regular follow-up with echocardiography and ECG is recommended.
Hypertrophic cardiomyopathy is the most common inherited heart disease, with a prevalence of about 1/500 (0.2%) in the general population. In large echocardiography-based population studies, left ventricular hypertrophy meeting the criteria for hypertrophic cardiomyopathy is found in about 1 in 200 adults. More than about 20 million people worldwide are estimated to be affected, but a considerable number of patients remain undiagnosed.
The non-obstructive subtype accounts for about 60~70% of all hypertrophic cardiomyopathy. About 25% of patients have no obstruction at rest but develop latent (labile) obstruction with the Valsalva maneuver or exercise, and about 25% have obstruction at rest (obstructive subtype). It occurs in both sexes, but diagnosis is more common in men, which is related to the tendency for symptoms and the degree of hypertrophy to be more severe in men. Recent studies have reported that women are underdiagnosed and that, even with the same mutation, women tend to show more severe symptoms at a later age.
In Korea, analyses of National Health Insurance Service (NHIS) big data and the Korean HCM Registry estimate the prevalence of hypertrophic cardiomyopathy at about 1~2 per 10,000 population, somewhat lower than in Western countries. This is likely the effect of underdiagnosis. Hypertrophic cardiomyopathy occurs in all races, but some studies have reported greater severity and more frequent diagnostic delay in Black patients. Non-obstructive hypertrophic cardiomyopathy is eligible for Special Copayment Reduction (V127) registration, and copayment reduction benefits are provided after registration.
Sudden death in athletes: hypertrophic cardiomyopathy is the most common single cause of sudden death in athletes under 35 years of age and has been reported to account for about 36% of all athlete sudden deaths in the United States (later studies tend to show lower proportions). There is a risk of sudden death from ventricular arrhythmias even in the non-obstructive subtype, and recommendations restricting sports participation to prevent exercise-related sudden death are an important clinical issue.
The pathophysiology of non-obstructive hypertrophic cardiomyopathy is multilayered, starting with sarcomere protein mutations and leading to a cascade of changes at the cellular, tissue and organ levels. The core molecular mechanism is sarcomere hyperactivation, which is the main cause of increased ATP consumption, increased calcium sensitivity and diastolic dysfunction.
Changes at the cardiomyocyte level: mutant sarcomere proteins (especially MYH7, MYBPC3) alter cross-bridge mechanics, so myosin-actin interaction is prolonged or its efficiency is reduced. Mutations in the troponin complex (troponin T, I, tropomyosin), the calcium-regulating proteins, increase contractile sensitivity to calcium and delay relaxation. As a result, cardiomyocyte energy consumption increases, and the energy-deficient state activates hypertrophic signaling pathways (calcineurin-NFAT, mTOR, etc.), inducing myocardial hypertrophy.
Changes at the tissue level: myocyte disarray develops along with cardiomyocyte hypertrophy. In normal myocardium the myocardial fibers are arranged in parallel, but in hypertrophic cardiomyopathy the fibers are arranged in random directions, forming the anatomical substrate for abnormal electrical conduction and ventricular arrhythmias. Interstitial fibrosis appears around cardiomyocytes and as replacement fibrosis (scar tissue after cell necrosis), and is identified as LGE (late gadolinium enhancement) on cardiac MRI. Fibrosis worsens diastolic dysfunction, forms an arrhythmic substrate and is a precursor change of declining systolic function (end-stage dilated transformation).
Hemodynamics of the non-obstructive subtype: diastolic dysfunction is prominent even in the non-obstructive subtype without left ventricular outflow tract obstruction. Filling of the hypertrophied left ventricle is impaired, raising the left ventricular end-diastolic pressure (LVEDP), which leads to elevated pulmonary venous pressure and pulmonary congestion during exercise. Microvascular dysfunction is also an important mechanism: small vessels within the hypertrophied, fibrotic myocardium lose their capacity to dilate, causing myocardial ischemia. This is the main mechanism of chest pain and promotes myocardial fibrosis.
Mechanism of sudden death: premature ventricular contractions, nonsustained ventricular tachycardia and sustained ventricular tachycardia/fibrillation are the direct causes of sudden death. Myocyte disarray, interstitial fibrosis and microvascular ischemia promote the formation of re-entrant circuits. In some patients, atrial fibrillation causes rapid ventricular conduction even without WPW syndrome or becomes a risk factor for thromboembolism.
The clinical symptoms of non-obstructive hypertrophic cardiomyopathy are highly variable, with a broad spectrum ranging from completely asymptomatic to severe heart failure symptoms. Because the non-obstructive subtype has no left ventricular outflow tract pressure gradient, it lacks the features of the obstructive subtype such as worsening of the systolic murmur with the Valsalva maneuver and worsening of symptoms on standing, and symptoms due to diastolic dysfunction and microvascular ischemia predominate.
Exertional dyspnea is the most common symptom of hypertrophic cardiomyopathy overall and is also the main symptom in the non-obstructive subtype. It is caused by elevated left ventricular filling pressure due to diastolic dysfunction and failure to increase cardiac output during exercise. Initially it appears only during strenuous exercise, but as the disease progresses it occurs even during daily activities. In severe cases, nocturnal dyspnea (orthopnea, PND) may appear.
Chest pain is non-ischemic chest pain occurring mainly during exercise or stressful situations, caused by subendocardial ischemia due to microvascular dysfunction and increased myocardial oxygen demand. Chest pain of typical anginal character can occur even without coronary artery disease, which is an important clue to the diagnosis of hypertrophic cardiomyopathy.
Syncope and presyncope: syncope during exercise can be a prodrome of sudden death and is therefore clinically very important. The causes act in combination: reduced cerebral blood flow due to failure to increase cardiac output during exercise, ventricular arrhythmias (nonsustained or sustained ventricular tachycardia) and vasovagal reactions. Syncope occurring during or immediately after exercise in particular is likely to be due to ventricular arrhythmia and requires immediate cardiac electrophysiological evaluation.
Palpitations: various arrhythmias such as atrial fibrillation, atrial flutter, premature ventricular contractions and nonsustained ventricular tachycardia cause palpitations. The prevalence of atrial fibrillation in hypertrophic cardiomyopathy is 4~6 times higher than in the general population, and left atrial enlargement, fibrosis and elevated ventricular filling pressure promote atrial fibrillation. When atrial fibrillation occurs, cardiac output falls sharply and symptoms may worsen.
Sudden cardiac death (SCD) without prior symptoms: in some patients, sudden death may be the first presentation without any prodromal symptoms. This pattern is particularly prominent in young athletes, and family screening is sometimes subsequently carried out through investigation of the family history. There is a risk of sudden death from ventricular arrhythmias even in the non-obstructive subtype, and accurately assessing this risk is central to the decision on ICD implantation.
Physical findings in non-obstructive hypertrophic cardiomyopathy are relatively sparse compared with the obstructive subtype. The harsh systolic murmur characteristic of the obstructive subtype, the increase in the murmur with the Valsalva maneuver and the spike-and-dome pattern of the carotid pulse are absent or mild in the non-obstructive subtype.
Heart sound findings: an S4 (fourth heart sound) is often heard; it is produced when blood fills the hypertrophied ventricle and reflects diastolic dysfunction. A mild systolic murmur may be heard at the apex, but unlike the left ventricular outflow tract murmur it shows no dynamic change. With atrial fibrillation, irregular heart sounds are observed. When heart failure has progressed, signs of congestion such as an S3 (third heart sound), pulmonary crackles and lower limb edema may appear.
ECG findings: an abnormal ECG is seen in about 75~95% of patients with hypertrophic cardiomyopathy, an important point of distinction from athlete's heart, in which a normal ECG is common. Findings include meeting left ventricular hypertrophy criteria (Sokolow-Lyon criteria: SV1+RV5/V6 ≥35 mm), left axis deviation, ST-segment depression, T-wave inversion (especially in leads I, aVL, V4-V6), abnormal Q waves (a narrow, deep pattern in the inferior or lateral leads), bundle branch block and P-wave abnormalities (left atrial enlargement). In apical hypertrophic cardiomyopathy (apical HCM), giant negative T waves in V4-V5 are characteristic.
Echocardiographic findings: central to the diagnosis; it is diagnosed when an end-diastolic left ventricular wall thickness ≥15 mm (≥13 mm in first-degree relatives with a family history) or hypertrophy exceeding standardized criteria is confirmed and there is no other cause to explain it (hypertensive cardiac hypertrophy, aortic stenosis, etc.). In the non-obstructive subtype, asymmetric left ventricular hypertrophy (typically thickest in the anterior septum) is the main finding, and evidence of diastolic dysfunction appears on assessment of diastolic function (E/e', left atrial volume index). SAM (systolic anterior motion of the mitral valve) is typical of the obstructive subtype but absent or minimal in the non-obstructive form.
Cardiac MRI findings: cardiac MRI provides better anatomical resolution than echocardiography and allows more accurate assessment of hypertrophy of the apex, lateral wall and papillary muscles in particular. Late gadolinium enhancement (LGE) visualizes myocardial fibrosis/scarring, and LGE positivity (especially LGE ≥15% of LV mass) is an independent predictor of arrhythmic sudden death and heart failure risk. Myocardial T1 mapping and measurement of extracellular volume (ECV) can also quantify diffuse fibrosis not revealed by LGE.
Universal screening of the general population for hypertrophic cardiomyopathy is not recommended because evidence of cost-effectiveness is insufficient. However, systematic screening is strongly recommended for relatives (first-degree relatives) of affected patients and for high-risk athlete groups.
Family screening (cascade screening): first-degree relatives (parents, siblings, children) of patients confirmed with hypertrophic cardiomyopathy must undergo screening. The main screening methods are echocardiography and ECG, and when a pathogenic gene variant has been identified in the family, targeted genetic testing for that variant is the most accurate and efficient method. Family members with a negative genetic test need no further cardiac testing, but for those who are genetically positive and currently phenotype-negative (genotype-positive/phenotype-negative, G+P-), regular echocardiography/ECG follow-up is recommended. Because the phenotype may emerge during growth, children and adolescents are followed every 12~18 months and adults every 3~5 years.
Cardiac screening of athletes: before participation in competitive sports, pre-participation screening is performed with a 12-item assessment (Italian protocol) or 14-item assessment (US AHA) including ECG and echocardiography. Because hypertrophic cardiomyopathy is a major cause of sudden death in athletes, athletes with exertional syncope, chest pain, palpitations, a family history or abnormal ECG findings must undergo further evaluation by echocardiography.
Newborn and pediatric screening: newborn screening for hypertrophic cardiomyopathy is not currently recommended. In genetically positive children the phenotype may appear as early as childhood or as late as adolescence or adulthood, and because the timing of expression is uncertain, regular follow-up is needed. In carriers of MYBPC3 mutations expression is relatively late (after the 40s), whereas MYH7 mutations can cause severe hypertrophy even in childhood. When severe myocardial hypertrophy is found in the neonatal period or infancy, differentiation of metabolic diseases such as Pompe disease, Danon disease and mitochondrial cardiomyopathy comes first.
Limitations of general screening: screening for hypertrophic cardiomyopathy by ECG alone has low specificity and many false positives. Echocardiography is operator-dependent, and apical hypertrophic cardiomyopathy or minimal hypertrophy can be missed on standard echocardiography. Cardiac MRI is limited by cost and accessibility for use as a screening tool.
The diagnosis of non-obstructive hypertrophic cardiomyopathy is defined as hypertrophy with an end-diastolic left ventricular wall thickness ≥15 mm (≥13 mm in first-degree relatives with a family history) on echocardiography or cardiac MRI, with exclusion of other causes that could explain it (hypertensive cardiac hypertrophy, aortic stenosis, amyloidosis, Fabry disease, etc.). A left ventricular outflow tract pressure gradient < 30 mmHg at rest and on provocation is the diagnostic requirement for the non-obstructive subtype.
Transthoracic echocardiography (TTE): the most important first-line diagnostic tool. Two- and three-dimensional echocardiography is used to assess left ventricular wall thickness (end-diastolic, all segments), left ventricular volume and systolic function (LVEF), diastolic function (E/e', E/A ratio, left atrial volume index) and right ventricular function. Doppler examination assesses the left ventricular outflow tract pressure gradient (before and after Valsalva) and the presence and severity of mitral regurgitation. In the non-obstructive subtype, an LV outflow tract gradient < 30 mmHg at rest and < 30 mmHg even after Valsalva is confirmed. Exercise stress echocardiography assesses whether latent obstruction is provoked during exercise.
Cardiac MRI (CMR): an essential test when anatomical assessment by echocardiography is insufficient, when apical or lateral wall hypertrophy is suspected, when the underlying diagnosis is uncertain, and for differentiation of genetic phenocopies. Cine imaging quantifies left ventricular volume, mass and function, and late gadolinium enhancement (LGE) measures the extent of myocardial fibrosis. LGE patterns (midwall LGE within the hypertrophied septum, crescent-shaped pattern) are characteristic of hypertrophic cardiomyopathy, and the concordance between LGE sites and the origin sites of high-risk arrhythmias for sudden death is being studied. T1 mapping and ECV analysis quantify diffuse fibrosis.
ECG and 24-hour Holter monitoring: the 12-lead ECG is used to support the diagnosis and to assess hypertrophy patterns related to hypertrophic cardiomyopathy and arrhythmias. 24- or 48-hour Holter monitoring is important for detecting nonsustained ventricular tachycardia (NSVT), and NSVT is one of the factors in sudden death risk assessment.
Exercise stress testing (treadmill test): assesses reproduction of symptoms during exercise, exercise capacity, the blood pressure response to exercise (abnormal blood pressure response = rise < 20 mmHg) and whether arrhythmias are provoked during exercise. An abnormal blood pressure response is one of the risk factors for sudden death.
Genetic testing: after clinical diagnosis or for family screening, NGS of a hypertrophic cardiomyopathy gene panel (including at least MYH7, MYBPC3, TNNT2, TNNI3, TPM1, MYL2, MYL3, ACTC1, CSRP3, etc.) is recommended. The diagnostic yield is about 40~60%. To differentiate Fabry disease, GLA gene testing (especially with onset at age 35~60 and LGE confined to the inferolateral wall) or measurement of plasma alpha-galactosidase A activity may be needed.
Blood tests: BNP/NT-proBNP is useful for assessing and following the severity of heart failure. Troponin elevation is associated with myocardial injury/fibrosis. When Fabry disease is suspected, alpha-galactosidase A activity is measured, and when amyloidosis is suspected, serum protein electrophoresis and immunofixation electrophoresis are performed.
Treatment of non-obstructive hypertrophic cardiomyopathy broadly consists of ① symptom-controlling drug therapy, ② prevention of arrhythmias and sudden death, ③ management of atrial fibrillation, ④ treatment of end-stage heart failure and ⑤ new sarcomere-targeted therapies. In the non-obstructive subtype there is no indication for the septal myectomy or alcohol septal ablation used in the obstructive subtype.
Symptom-controlling drugs: beta-blockers are the first-line drugs for hypertrophic cardiomyopathy, as they reduce heart rate to prolong diastolic filling time, reduce myocardial oxygen demand and suppress exercise-induced arrhythmias. Extended-release metoprolol, atenolol, carvedilol and others are used. When beta-blockers are not tolerated or are contraindicated, verapamil (a non-dihydropyridine calcium channel blocker) can be used, and improvement of diastolic function and relief of symptoms have been reported. However, because verapamil can worsen obstruction in the obstructive subtype through its vasodilating effect, it can be used more safely in the non-obstructive subtype. Disopyramide is used mainly in the obstructive subtype for its negative inotropic effect, but its role in the non-obstructive form is limited.
Prevention of sudden death — implantable cardioverter-defibrillator (ICD): the ICD is the key means of preventing sudden death in hypertrophic cardiomyopathy. The 2022 AHA/ACC guideline recommends ICD implantation when one or more of the following high-risk factors are present: ① prior ventricular fibrillation or sustained ventricular tachycardia, ② sudden death related to hypertrophic cardiomyopathy in a family member, ③ unexplained syncope, ④ NSVT on 24-hour Holter, ⑤ maximum left ventricular wall thickness ≥30 mm, ⑥ abnormal blood pressure response to exercise. Risk-based ICD decisions using the recently developed HCM Risk-SCD score (5-year sudden death risk ≥6% = ICD recommended, 4~6% = individualized) are applied in the European guideline. The same indications for ICD implantation apply to the non-obstructive subtype when risk factors are present.
Management of atrial fibrillation: atrial fibrillation is the most common sustained arrhythmia in hypertrophic cardiomyopathy and is associated with worsening symptoms and increased stroke risk. When atrial fibrillation develops in any patient with hypertrophic cardiomyopathy, oral anticoagulation (direct oral anticoagulants, DOAC) is recommended regardless of the CHA2DS2-VASc score. Sinus rhythm is maintained through rate control (beta-blockers, verapamil) and rhythm control (amiodarone, sotalol, catheter ablation). Catheter ablation (pulmonary vein isolation) is an option for drug-refractory atrial fibrillation, but the recurrence rate is high.
Mavacamten (Camzyos): a selective inhibitor of cardiac myosin ATPase that corrects sarcomere hyperactivation by reducing excessive cross-bridge formation. It was approved by the FDA in 2022 and the EMA in 2023 for symptomatic obstructive hypertrophic cardiomyopathy (NYHA II-III, left ventricular outflow tract pressure gradient ≥50 mmHg). In the MAVERICK-HCM phase 2 trial in the non-obstructive subtype, reductions in NT-proBNP and cardiac troponin I and improvement in diastolic function were reported, and a phase 3 trial is under way. Because of the risk of myocardial depression (reduced LVEF), it is contraindicated when LVEF < 55%, and caution is needed regarding increased concentrations when combined with strong CYP2C19 inhibitors.
Treatment of end-stage heart failure: in about 5% of patients with hypertrophic cardiomyopathy, an 'end-stage (burnt-out)' or 'dilated transformation' phase characterized by left ventricular dilatation and reduced systolic function develops. At this stage, standard heart failure therapy (ACE inhibitors/ARB/ARNI, beta-blockers, diuretics, MRA, SGLT2 inhibitors) is applied. In patients with the non-obstructive subtype, diuretics are useful for improving symptoms through preload reduction, whereas in the obstructive subtype excessive preload reduction may worsen obstruction. In end-stage heart failure, heart transplantation is the definitive treatment.
The prognosis of non-obstructive hypertrophic cardiomyopathy is quite favorable when appropriately managed at a specialist cardiac center. Annual mortality for hypertrophic cardiomyopathy as a whole is about 0.5~1%, greatly improved compared with the past. Some studies have reported a somewhat worse prognosis for the non-obstructive subtype than for the obstructive subtype, but with appropriate management at a specialist center, life expectancy can be kept close to that of the general population.
Risk of sudden death: sudden death related to hypertrophic cardiomyopathy is about 0.5~1% per year (in adult specialist centers). The high-risk group for sudden death includes patients with a history of prior ventricular fibrillation or sustained ventricular tachycardia, unexplained syncope, a family history of sudden death, NSVT on 24-hour Holter, maximum left ventricular wall thickness ≥30 mm, an abnormal blood pressure response to exercise, or extensive myocardial LGE (≥15% of LV mass). After ICD implantation, the rate of appropriate defibrillation therapy is reported to be about 4~5% per year (in the indicated group).
Heart failure and functional decline: when diastolic dysfunction persists and worsens in the non-obstructive subtype, exercise capacity gradually declines. About 5% progress to the dilated phase or end-stage heart failure, in which case the prognosis is markedly poor. Extensive LGE on cardiac MRI, high ECV and elevated NT-proBNP are predictors of this progression.
Atrial fibrillation and stroke: atrial fibrillation increases the risk of stroke in hypertrophic cardiomyopathy about 8-fold. Anticoagulation can greatly reduce the stroke risk, and early detection and treatment of atrial fibrillation are important. The cumulative incidence of atrial fibrillation reaches about 20~25% at 10 years after diagnosis.
Pregnancy and prognosis: pregnancy in women with hypertrophic cardiomyopathy can mostly proceed safely, but in high-risk groups (severe diastolic dysfunction, atrial fibrillation, ICD implantation, severe hypertrophy) the risk of cardiac complications during pregnancy increases. Prenatal cardiac evaluation and multidisciplinary care are recommended. Genetic counseling is also needed regarding the 50% probability of the mutation being transmitted to the fetus.
Exercise participation and prognosis: in the past, patients with hypertrophic cardiomyopathy were barred from almost all competitive sports, but recent studies and the 2024 AHA/ACC guideline are shifting toward allowing some exercise participation based on individualized risk assessment in patients at low risk of sudden death. Low- to moderate-intensity exercise helps maintain cardiopulmonary function and improve quality of life, and individualized counseling on participation in regular exercise programs is recommended.
Because of the nature of genetic disease, complete primary prevention (preventing onset) of non-obstructive hypertrophic cardiomyopathy is limited with current technology, and the main focus is on preventing complications (sudden death, heart failure, stroke) through early detection.
Genetic counseling and family screening: all first-degree relatives (parents, siblings, children) of patients confirmed with hypertrophic cardiomyopathy should receive genetic counseling and undergo screening with echocardiography and ECG. When a pathogenic variant has been identified in the family, targeted genetic testing for that variant is performed, and in those who are variant-positive and currently phenotype-negative, regular follow-up allows early treatment to be started when the phenotype emerges. Preimplantation genetic testing (PGT) is considered in some families as a way to prevent the birth of affected children. Because genetic counseling involves complex concepts such as incomplete penetrance, variable expressivity and uncertainty in genetic test results, the involvement of a specialist genetic counselor is important.
Prevention of sudden death — ICD and risk stratification: prevention of sudden death centers on ICD implantation, for which systematic risk stratification is essential. All patients with non-obstructive hypertrophic cardiomyopathy should undergo assessment of sudden death risk factors at diagnosis and at regular follow-up. Sudden death is prevented by ICD implantation in carriers of high-risk factors, and risk stratification should combine the HCM Risk-SCD calculator with clinical judgment. The subcutaneous ICD (S-ICD) is increasingly used in patients with hypertrophic cardiomyopathy because of its advantages of fewer complications and easier removal.
Activity and lifestyle recommendations: patients with hypertrophic cardiomyopathy should avoid strenuous competitive sports and determine their activity level according to an individualized exercise prescription. Dehydration, excessive heat exposure and sudden initiation of high-intensity exercise can increase hemodynamic stress and require caution. Vasodilators that sharply lower heart rate and blood pressure (high-dose diuretics, alpha-blockers, nitrates, etc.) can reduce cardiac output through preload reduction and should be used cautiously. Alcohol carries a risk of transient vasodilation and triggering arrhythmias, so limiting it is recommended.
Prevention of atrial fibrillation and stroke: anticoagulation is the key to preventing stroke when atrial fibrillation occurs, and in patients with hypertrophic cardiomyopathy anticoagulation is started as soon as atrial fibrillation develops, regardless of the CHA2DS2-VASc score. Regular ECGs, long-term Holter monitoring or an implantable loop recorder (ILR) for early detection of atrial fibrillation are considered in some high-risk patients.
Regular follow-up: all patients with non-obstructive hypertrophic cardiomyopathy should undergo a comprehensive evaluation every 1~2 years at a specialist cardiac center (a dedicated hypertrophic cardiomyopathy clinic is recommended), including echocardiography, ECG, 24-hour Holter monitoring, exercise stress testing and BNP/NT-proBNP measurement. Early evaluation is needed for worsening symptoms, new atrial fibrillation, syncope or functional decline. Repeat cardiac MRI is recommended every 2~5 years or when there is clinical change.
Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(4):372-389. DOI: 10.1016/j.jacc.2021.12.002
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020;76(25):e159-e240. DOI: 10.1016/j.jacc.2020.08.045. PMID: 33229116.
Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733-2779. DOI: 10.1093/eurheartj/ehu284. PMID: 25173338.
Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM). Lancet. 2020;396(10253):759-769. DOI: 10.1016/S0140-6736(20)31792-X. PMID: 32871100.
Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. Circulation. 2018;138(14):1387-1398. DOI: 10.1161/CIRCULATIONAHA.117.033200. PMID: 29685932.
Maron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. JACC Heart Fail. 2018;6(5):353-363. DOI: 10.1016/j.jchf.2017.09.011. PMID: 29477390.
Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20(1):1-8. DOI: 10.1136/hrt.20.1.1. PMID: 13499257.
Christiaans I, van Engelen K, van Langen IM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace. 2010;12(3):313-321. DOI: 10.1093/europace/eup431. PMID: 20042411.
Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295-303. DOI: 10.1056/NEJMoa021332. PMID: 12540642.
Kim LK, Swaminathan RV, Looser P, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy. JAMA Cardiol. 2016;1(3):324-332. DOI: 10.1001/jamacardio.2016.0252. PMID: 27438117.